Wiley Matthew T.'s Form 4 filing
BioXcel Therapeutics, Inc. (BTAIQ) · filed Apr 8, 2024
- Accession no.
- 0001104659-24-044859
- Filed
- Apr 8, 2024
- Trade date
- Mar 15-Apr 4, 2024
- Filing delay
- 24 daysLate
- Rule 10b5-1 plan
- Checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $2.66K. It was filed 24 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wiley Matthew T.CIK 0001759703 | Officer (CHIEF COMMERCIAL OFFICER) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2024 | Common Stock | MOption exerciseAcquired | +3,000 | – | – | 3,000 | Direct | |
| Apr 4, 2024 | Common Stock | SSaleDisposed | −1,008 | $2.64 | −$2,661.12 | 2,992 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 15, 2024 | Common Stock | MOption exerciseAcquired | +3,000 | $0.00 | $0 | 9,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.